Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Regen Biopharma ( (RGBP) ) just unveiled an announcement.
On August 5, 2025, Regen Biopharma, Inc. entered into a securities purchase agreement with Labrys Fund II LP, resulting in the issuance of a 6% convertible promissory note valued at $100,000. This agreement allows Labrys the option to convert the note into common stock, potentially impacting the company’s stock trading dynamics and financial strategy.
More about Regen Biopharma
Regen Biopharma, Inc. operates in the biotechnology industry, focusing on developing innovative treatments and therapies. The company is involved in the research and development of products aimed at addressing critical medical needs.
Average Trading Volume: 74,769
Technical Sentiment Signal: Sell
Current Market Cap: $1.63M
For a thorough assessment of RGBP stock, go to TipRanks’ Stock Analysis page.